UNASSIGNED: 1084 Background: @entity5345 -associated @entity0 have pathologic features and biologic behavior that are distinct from @entity0 while @entity2674 @entity5 are indistinguishable. Comparative survival studies have reported conflicting results and recent studies suggest relative resistance to @entity3907 -based chemotherapy in @entity1 with @entity5345 mutations. To determine if there are differences in long-term outcomes for @entity5345 , @entity2674 and high-risk non-carriers with @entity0 based on adjuvant therapy received, we conducted a retrospective analysis in US and Italian @entity1 . METHODS: @entity1 diagnosed with @entity0 between January 1, 1990 and December 31, 2008 were identified at the University of Chicago Cancer Risk Clinic and the Veneto Institute of Oncology in Padua. There were 80 @entity5345 carriers, 78 @entity2674 carriers and 177 high-risk non-carriers ascertained within the same time period. End points were @entity1349 ( @entity1349 ) and @entity1349 ( @entity1349 ) by type of adjuvant chemotherapy received. Hazard Ratios (HR) and 95% Confidence Intervals (95% CI) were calculated from Cox proportional hazard models. A multivariate analysis was used to adjust for year at diagnosis, stage, grade and @entity1782 (ER) status. RESULTS: The median follow up was 4.98 (0.03-18.9). The @entity1349 -adjusted hazard ratios were not significantly different among mutation carriers and non-carriers (HR among @entity5345 carriers, 0.52; 95% CI, 0.21 to 1.31; HR among @entity2674 carriers, 0.68; 95% CI, 0.31 to 1.48; P=0.326). The @entity1349 -adjusted hazard ratios were not significantly different (HR among @entity5345 carriers, 1.24; 95% CI, 0.45 to 3.45; HR among @entity2674 carriers, 0.89; 95% CI, 0.33 to 2.38; P=0.837). Ten year survival was 78% for @entity5345 , 83% for @entity2674 and 92% for non-carriers, respectively. The risk of recurrence and @entity204 was also not statistically significant among @entity1 treated with different chemotherapy regimens. CONCLUSIONS: @entity1349 and @entity1349 survival are similar for carriers of a BRCA mutation and non-carriers.

Adjuvant chemotherapy in American and Italian XXXX with @entity5345 /2-associated @entity0 .

@entity1 :: ('9606', 'Species') :: ['Patients', 'patients'] @entity1782 :: ('2099', 'Gene') :: ['Estrogen Receptor'] @entity0 :: ('MESH:D001943', 'Disease') :: ['breast cancers', 'breast cancer', 'sporadic breast tumors', 'stage I, II, and III breast cancer'] @entity5345 :: ('672', 'Gene') :: ['BRCA1'] @entity5 :: ('MESH:D009369', 'Disease') :: ['tumors'] @entity2674 :: ('675', 'Gene') :: ['BRCA2'] @entity3907 :: ('MESH:C080625', 'Chemical') :: ['taxane'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity1349 :: ('MESH:D011475', 'Disease') :: ['OS', 'RFS', 'recurrence-free survival', 'overall survival']
@entity1 :: (9606,Species) :: ['patients']
